The Determination and Control of Genotoxic Impurities in APIs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Determination and Control of Genotoxic Impurities in APIs
The authors provide an overview of methods for the quantitative determination of genotoxic impurities (GTIs) in active pharmaceutical ingredients.


Pharmaceutical Technology
Volume 35, pp. s24-s30

References

1. ICH, S2 (R1) Guideline on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use (2008).

2. T. McGovern and D.J. Kram, Trends Analyt. Chem. 25 (8), 790–795 (2006).

3. ICH, Q3A (R2) Guideline on Impurities in New Drug Substances (2006).

4. ICH, Q3C(R4) Guideline for Residual Solvents (2009).

5. R. Kroes et al., Food Chem. Toxicol. 42 (1), 65–83 (2004).

6. EMA, Guideline on the Limits of Genotoxic Impurities (London, January 2007).

7. EMA, Guideline on the Limits of Genotoxic Impurities (February 2009).

8. L. Muller et al., Regul. Toxicol. Pharmacol. 44 (3), 198–211 (2006).

9. M. Sun, D.Q. Liu, and A.S. Kord, Org. Process Res. Dev. 14 (4), 977–985 (2010).

10. D.Q. Liu, M. Sun, and A.S. Kord, J. Pharm. Biomed. Anal. 51 (5), 999–1014 (2010).

11. D.Q. Liu et al., J. Pharm. Biomed. Anal. 50 (2), 144–150 (2009).

12. N.V.V.S.S. Raman et al., J. Pharm. Biomed. Anal. 48 (1), 227–230 (2008).

13. D.P. Elder et al., J. Pharm. Sci. 99 (7), 2948–2961 (2010).

14. L. Bai et al., J. Chromatogr. A 1217 (3), 302–306 (2010).

15. E.J. Delaney, Regul. Toxicol. Pharmacol. 49 (2), 107–124 (2007).

16. K. Ramakrishna, J. Pharm. Biomed. Anal. 46 (4), 780–783 (2008).

17. R. Alzaga et al., J. Pharm. Biomed. Anal. 45 (3), 472–479 (2007).

18. N.V.V.S.S. Raman et al., Talanta 77 (5), 1869–1872 (2009).

19. A. Teasdale, Org. Process Res. Dev. 13 (3), 429–433 (2009).

20. F.N. Onyezili, Analyst 114 (1), 789–791 (1989).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here